Documente Academic
Documente Profesional
Documente Cultură
Epidemiology
The background rate of infection in the general population is extremely low at less than 1 case per
million population per year.
When HIV was first characterised, PCP affected up to 75% of HIV-infected individuals. Current
rates of infection in the HIV-positive population in the developed world are about 1020%.
The incidence of PCP in HIV-positive patients has been significantly reduced by prophylactic
medication and highly active antiretroviral therapy (HAART). [3]
In the developing world, rates of PCP are lower, possibly due to poor survival with HIV,
underdiagnosis and prior pulmonary infection with TB and other organisms.
Risk factors
PCP tends to affect HIV positive patients who have a CD4 count below 200 cells/mm 3
HIV patients with oral thrush or fever, or AIDS-defining diagnosis
Patients taking steroids or other immunosuppressants
Patients with haematological malignancy
Organ-transplant recipients
Congenital immune deficiency, eg thymic aplasia, severe combined immune deficiency (SCID),
hypogammaglobulinaemia
Severe malnutrition (poor nutrition in HIV-positive individuals increases risk)
Presentation
Cough is usually non-productive but productive cough may occur in up to a third of patients
Exertional dyspnoea
Fever
Tachypnoea
Chest pain
There may be signs of AIDS such as thrush, oral hairy leucoplakia or Kaposi's sarcoma
Respiratory examination is highly variable and often normal. Scattered crackles and wheeze may
be present, or rarely signs of focal consolidation
Pulse oximetry may show low SaO 2 at rest
Page 2 of 6
may show low SaO 2 at rest
Extrapulmonary disease may manifest as hepatosplenomegaly, lymphadenopathy or ocular
disease
Differential diagnosis
Bacterial or viral pneumonia
Mycobacterium avium-intracellulare complex infection
Atypical pneumonia
Pulmonary Kaposi's sarcoma
Tuberculosis
Influenza
Cytomegalovirus infection
Aspergillosis
Measles
Varicella (chickenpox) pneumonitis
Coxiella burnetii (Q fever)
Thoracic actinomycosis
Pulmonary nocardiosis
Lymphocytic interstitial pneumonia (associated with autoimmune disease)
Pulmonary embolism
Investigations
Bloods:
Elevated lactate dehydrogenase is indicative of the diagnosis but not highly specific or
sensitive.
Arterial blood gases may show hypoxia and hypocarbia due to hyperventilation.
The alveolar-arterial oxygen tension gradient may be increased.
The use of serum (1-->3) beta-D-glucan levels (high in PCP) is currently being
investigated as a diagnostic test. [4]
Radiology:
Chest X-ray can be normal or show perihilar fluffy shadows or pneumothorax.
CT imaging shows ground glass infiltrates but has low sensitivity and specificity.
Gallium scanning is highly sensitive but with low and variable specificity.
Microbiology:
The organism cannot be routinely cultured and is detected by staining of the cyst wall or
trophozoite in sputum samples, usually with silver-based stains. Repeated samples may
need to be taken to confirm the diagnosis.
Sputum may be collected following inhalation of nebulised saline and/or chest
physiotherapy and should also be sent for routine and mycobacterial culture.
If sputum is negative but PCP is still suspected, then bronchoscopy with
bronchoalveolar lavage or transbronchial biopsy may detect the organism.
Open lung biopsy may occasionally be employed.
Pulmonary function tests:
May show a modest reduction in the vital capacity (VC) and the total lung capacity (TLC).
Most consistent abnormality is a decrease in the single-breath diffusing capacity for
carbon monoxide (DLCO), which has a sensitivity of 89%.
Page 3 of 6
Moderate:
Breathlessness on minimal exercise, fever (with or without sweats)
Arterial blood gases and oxygen saturation at rest, on air: PaO2 811 kPa; SaO2 91-96%
Chest X-ray: diffuse interstitial shadowing
Severe:
Breathlessness at rest, persistent fever and cough
Arterial blood gases and oxygen saturation at rest, on air: PaO2 <8 kPa; SaO2 <91%
Chest X-Ray: extensive interstitial shadowing, with or without alveolar shadowing
Management
Early diagnosis greatly aids successful therapy.
Mild cases may be treated with oral medication as outpatients. Moderate to severe cases usually
require hospitalisation and intravenous therapy.
Treating empirically without confirmation of the diagnosis may be necessary but is best avoided if
possible, due to the danger of missing other causes for the symptoms.
Patients often deteriorate 35 days after starting treatment. This is thought to be due to
inflammation caused by dead pneumocystis organisms.
Treatment is usually given for 23 weeks.
Mild-to-moderate disease
High-dose co-trimoxazole (trimethoprim-sulfamethoxazole) is the drug of choice. Concomitant
host disease influences susceptibility to adverse drug reactions. HIV increases the risk of toxicity
with many drugs including co-trimoxazole. Adverse effects occur in up to 65% of those receiving
the drug and 50% will discontinue treatment. Hypersensitivity reactions are most common in such
patients and include fever and maculopapular rash. Co-trimoxazole is usually well tolerated in
immunocompetent patients [6] but should be avoided in those with severe hepatic or renal
dysfunction and porphyria. It is also best avoided during pregnancy and breast-feeding. Sideeffects are numerous and include nausea, vomiting, skin reactions, neutropenia,
thrombocytopenia, hepatitis and cholestatic jaundice. [7]
Alternatives if the patient is unable to tolerate co-trimoxazole are:
Atovaquone - this has similar efficacy as pentamidine and is better tolerated than
parenteral pentamidine, co-trimoxazole or dapsone. However, oral atovaquone has
limited and unpredictable bioavailability. [8]
Dapsone with trimethoprim - dapsone is given intravenously or occasionally in nebulised
form in the treatment of PCP.
Clindamycin with primaquine - clindamycin is associated with the development of
antibiotic-associated colitis and treatment must be immediately discontinued if diarrhoea
develops.
Inhaled pentamidine isetionate - this is restricted to specialist care, under careful patient
observation and with laboratory monitoring.
Severe disease
Intravenous high-dose co-trimoxazole is first-line treatment but toxic effects mean it may not be
tolerated.
Pentamidine isetionate:
Given by intravenous infusion, is used for patients who either cannot tolerate cotrimoxazole or who have not responded to it.
Can cause severe hypotension during or immediately after infusion; blood pressure and
glucose should be carefully monitored.
Page 4 of 6
Oral prednisolone or parenteral hydrocortisone:
Steroids are an important adjunctive therapy for patients with moderate-to-severe
infections associated with HIV infection.
Steroids are usually given in high dosage for 5-7 days and then the dose is reduced and
continued for a further two weeks.
Steroid treatment should be started at the same time as the antimicrobial therapy and
withdrawn before antimicrobial treatment is complete.
Trimethoprim and dapsone may be used in combination for mild-to-moderate PCP, although unlicensed. [7]
An alternative regimen should be used in patients with G6PD deficiency. [7]
Drug resistance
Prior to the HIV epidemic, co-trimoxazole was rarely used in developed countries due to concerns
regarding toxicity. Resistance to co-trimoxazole in such countries was therefore very low. However since the
use of co-trimoxazole and dapsone [9] for the treatment and long-term prophylaxis of PCP and
toxoplasmosis, increased levels of resistance have been detected. [10]
A number of single base polymorphisms have been demonstrated in the P. jirovecii nucleotide sequence
that codes for dihydropteroate synthetase. These mutations may affect substrate binding and be
associated with the emergence of resistance to sulphonamides and dapsone. [11] Mutations in the
cytochrome b gene have been demonstrated in atovaquone-resistant P. jirovecii isolates, which are likely to
represent mechanisms of resistance. [8]
Findings linking mortality rates to the acquisition of the mutated P. jirovecii organism are inconsistent, which
is not surprising, since survival in HIV-positive patients depends on many other factors. However, it does
make assessment of the impact of drug resistance in such patients difficult and more research is required
to develop strategies to prevent the emergence of further resistance strains. [1] [9]
New drugs
New drugs against P. jirovecii are in development. Sordarin derivatives are a novel class of antifungal
compounds that inhibit protein synthesis. Animal models of infection have shown promising activity against
PCP with limited toxicity. Echinocandins and pneumocandins, which inhibit beta-glucan synthesis are also
being investigated. [12] [13] The promise of future new targets is expected with the annotation of the
pneumocystis genome. [14]
Prophylaxis
Drug prophylaxis reduces the incidence of PCP and lengthens the disease-free intervals between
episodes.
It should be considered for:
All patients with a history of the pneumocystis infection.
Severely immunocompromised patients.
All HIV-positive individuals once their CD4 T-cell count falls below 200 cells/mm 3. [7]
Prophylaxis should continue until immunity recovers sufficiently.
Page 5 of 6
Oral co-trimoxazole by mouth is the drug of choice.
Intermittent inhalation of pentamidine isetionate is used for patients unable to tolerate cotrimoxazole but it doesn't suppress extrapulmonary pneumocystosis.
Dapsone and atovaquone have also been used for prophylaxis.
Patients (particularly children) who start HAART and attain low HIV viral load and improved CD4
counts may have prophylactic therapy safely discontinued. [15] [16]
Complications
Respiratory failure
Acute respiratory distress syndrome
Worsening of condition after starting therapy
Pulmonary cyst formation
Pneumothorax
Haematogenous spread
Extrapulmonary infection (typically affects bone marrow, liver, spleen, lymph nodes, gut and eyes)
Prognosis
The use of HAART has made significant changes to the prognosis of HIV-related pulmonary infections.
Mortality is about 1020% in mild-to-moderate cases, [17] rising to 4050% in patients who require artificial
ventilation. Due to restricted access to optimal medical care, PCP remains a common AIDS-defining illness
in developed nations and is associated with significant morbidity and mortality. [18]
EMIS
Page 6 of 6
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of
medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty
as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical
conditions. For details see our conditions.